 Connection
Sarah Lehman to Cardiomyopathy, Hypertrophic
This is a "connection" page, showing publications Sarah Lehman has written about Cardiomyopathy, Hypertrophic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.399 |
|
|
|
-
Lehman SJ, Crocini C, Leinwand LA. Targeting the sarcomere in inherited cardiomyopathies. Nat Rev Cardiol. 2022 06; 19(6):353-363.
Score: 0.649
-
Lehman SJ, Tal-Grinspan L, Lynn ML, Strom J, Benitez GE, Anderson ME, Tardiff JC. Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy. Circulation. 2019 03 19; 139(12):1517-1529.
Score: 0.527
-
Emter CA, Henze M, DuVall M, Lehman S, Lee L, Barthel B, Hawryluk NA, Madden M, Wu Y, Perry A, Beyer M, Wei E, Rupert C, Roof S, Peter A, DiNatale E, Cantrell S, Tolley J, Schlachter S, van der Velden J, Michels M, Seidman C, Ma W, Leinwand L, Campbell S, Ochala J, Bluemke D, Tharp D, Seidman J, Del Rio CL, Semigran M, Evanchik M, Koch K, Russell A. Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator. JCI Insight. 2026 Sep 22; 11(18).
Score: 0.222
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|